We are Sorry, This Page doesn't Exist

Pfizer Inc posted third-quarter profit well above analysts' estimates on higher sales of cancer drug Ibrance and arthritis medicine Xeljanz, encouraging the largest U.S. drugmaker to lift its earnings forecast for the year......»»

Pfizer Inc beat Wall Street estimates for quarterly profit and tweaked its earnings forecast for the year on Tuesday, as it reported rising sales of cancer drug Ibrance and pneumonia vaccine Prevnar, pushing shares in the drugmaker higher......»»

Drugmaker Merck & Co on Friday raised its full-year profit forecast after beating Wall Street estimates for quarterly profit as sales of blockbuster cancer drug Keytruda nearly doubled......»»

Gotham Therapeutics, a Manhattan-based biotech company, has received $54 million in Series A financing to advance research into a novel method of finding oncology drug candidates. The research was... To view the full story, click the title link......»»

Rain Therapeutics Inc. was set on Friday to be the fifth Bay Area life science company in eight days to debut on Nasdaq. The Newark cancer therapeutics business raised $125 million in an initial public offering that hit the middle of its price .....»»

Two Philadelphia-area biopharmaceutical companies focused on developing cancer therapies expect to raise a total of nearly $160 million from stock offerings Monday. The majority of the funds are expected to be raised by Prelude Therapeutics (NAS.....»»

Plus: Nurses union demands better worker protection for potential second wave of Covid-19 Homeless nonprofit seeks to mitigate new risks for drug users Manhattan startup raises $25M to... To view the full story, click the title link......»»

Sales of Bristol-Myers Squibb Co's cancer drug Abraxane have been suspended in China based on findings at a third-party manufacturing plant in the United States......»»

Context Therapeutics, a Philadelphia biopharmaceutical company focused on hormone-driven cancers, is teaming up with a Chinese biotech firm to advance the development of Context's lead new drug candidate. That experimental therapy, called onapristo.....»»

Pfizer Inc posted a quarterly profit on Tuesday that came in below Wall Street estimates, as sales of breast cancer drug Ibrance fell short of expectations......»»

Johnson & Johnson narrowly missed quarterly revenue estimates on Wednesday as sales of its blockbuster psoriasis medicine Stelara and cancer drug Imbruvica fell short of expectations......»»

Johnson & Johnson narrowly missed quarterly revenue estimates on Wednesday as sales of its blockbuster psoriasis medicine Stelara and cancer drug Imbruvica fell short of expectations......»»

Needham analyst raises target price after promising results of drug trialRelated Stocks: SGEN, XSWX:ROG, PBYI, ABBV,.....»»

Shares of Fate Therapeutics gained 37% after it shared promising data from one clinical and one preclinical study for its experimental cancer immunotherapy treatments. The company is testing two therapies, FT516 and FT500, in.....»»

Canada Goose Holdings Inc. stock is down 13% in Wednesday trading despite reporting earnings and sales that beat expectations. The outwear company didn't raise its guidance, Wells Fargo analysts note, whic.....»»

Johnson & Johnson boosted its profit forecast for the year on Tuesday after posting better-than-expected quarterly earnings on stronger prescription sales of its psoriasis treatment Stelara and cancer drug Imbruvica......»»

Insys Therapeutics Inc, has entered into sales agreements to unload some of its drug assets for a combined $29.2 million as the Chandler-based pharmaceutical firm works through bankruptcy filing proceedings. Insys will sell its naloxone and epinephrin.....»»

Insys Therapeutics Inc, has entered into sales agreements to unload some of its drug assets for a combined $29.2 million as the Chandler-based pharmaceutical firm works through bankruptcy filing proceedings. Insys will sell its naloxone and epinephrin.....»»

Nektar Therapeutics (NASDAQ: NKTR) shares were plummeting to a two-year low Friday following the release .....»»

Nektar Therapeutics (NASDAQ: NKTR) shares were plummeting to a two-year low Friday following the release of its quarterly results the prior afternoon, wiping away roughly $1.9 billion of its marke read more.....»»